Cocrystal Pharma Inc

Cocrystal Pharma Inc maintains a strong liquidity position, with a current ratio of 10.3 and cash and equivalents amounting to $21.84 million, which significantly exceeds its total liabilities of $3.96 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage. The price-to-book ratio of 0.77 suggests that the company is trading at a discount to its book value, which may reflect market skepticism about its current earnings potential. The company is currently unprofitable, with a net loss of $3.96 million and an operating loss of $4.16 million in the latest reporting period. Its return on equity (ROE) is -17.52%, and its return on assets (ROA) is -14.9%, both of which are significantly below the industry median for biotechnology firms. The company's EV/EBITDA ratio of 1.08 is also below the industry median, reflecting its current unprofitability and the market's low valuation of its earnings potential. Cocrystal Pharma Inc's revenue is concentrated in a limited number of segments and geographic regions, as disclosed in its financial filings. The company's operations are primarily focused on the United States, with no material international revenue reported in the latest financial data. The company's business is driven by its pipeline of drug candidates, with no disclosed revenue from commercialized products. The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest reporting period. Analysts have assigned a mean price target of $8.00, which is significantly higher than the current market price of $1.26, suggesting potential upside if the company achieves key development milestones. However, the company's operating cash flow is negative at -$4.50 million, and its free cash flow is -$3.93 million, indicating that it is not generating sufficient cash to fund operations without external financing. The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's reliance on external financing to fund operations introduces potential dilution risk in the future, particularly if it needs to raise additional capital to advance its drug candidates through clinical trials. The company's capital expenditures are minimal at -$8,000, indicating that it is not investing in significant physical assets at this time. Recent events, including analyst estimates and price targets, suggest that the market is optimistic about the company's long-term potential, despite its current unprofitability. The mean recommendation of 2.00 (on a scale of 1 to 5) indicates a "buy" rating, with one analyst issuing a "buy" recommendation and no strong buy or hold ratings. The high price target of $10.00 and the low price target of $6.00 suggest a wide range of expectations among analysts, reflecting the uncertainty surrounding the company's future performance.